THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED
Clinical trials for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED explained in plain language.
Never miss a new study
Get alerted when new THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED trials appear
Sign up with your email to follow new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood clotting disorder? daratumumab under study
Disease control Recruiting nowThis study is collecting information from 40 patients with a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have been treated with daratumumab. The goal is to see how well daratumumab works and how safe it is for patients whose disease d…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene hunt: can DNA explain a rare blood disorder?
Knowledge-focused Recruiting nowThis study looks at whether a specific gene, TNFAIP3, is linked to immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare blood clotting disorder. Researchers will compare genetic data from 400 people with iTTP and healthy volunteers to see if gene variations affect d…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC